PA
NRIX icon

Profund Advisors’s Nurix Therapeutics NRIX Stock Holding History

Profund Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$855K Sell
35,234
-31,759
-47% -$541K 0.02% 388
2026
Q1 		$1.04M Buy
66,993
+32,413
+94% +$537K 0.04% 335
2025
Q4 		$656K Buy
34,580
+14,125
+69% +$203K 0.02% 467
2025
Q3 		$189K Buy
20,455
+4,022
+24% +$41.8K 0.01% 995
2025
Q2 		$187K Sell
16,433
-6,754
-29% -$73K 0.01% 921
2025
Q1 		$275K Buy
23,187
+283
+1% +$4.73K 0.01% 722
2024
Q4 		$432K Buy
22,904
+3,866
+20% +$88.6K 0.02% 588
2024
Q3 		$428K Sell
19,038
-6,550
-26% -$148K 0.02% 597
2024
Q2 		$534K Sell
25,588
-7,472
-23% -$116K 0.02% 481
2024
Q1 		$486K Buy
+33,060
New +$356K 0.02% 586
2023
Q4 		– Sell
-17,233
Closed -$135K – 1147
2023
Q3 		$135K Sell
17,233
-4,016
-19% -$36.7K 0.01% 922
2023
Q2 		$212K Sell
21,249
-5,110
-19% -$52.1K 0.01% 941
2023
Q1 		$234K Buy
+26,359
New +$275K 0.01% 885

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Profund Advisors's NRIX Position: Q2 2026 in Review

Profund Advisors reduced its Nurix Therapeutics (NRIX) stake by 47% in Q2 2026, selling an estimated $541K and leaving 35,234 shares worth $855K. The position accounts for 0.02% of the portfolio, ranked #388.

Profund Advisors first reported a position in NRIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.04M in Q1 2026. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Profund Advisors held 35,234 shares of Nurix Therapeutics worth $855K as of Q2 2026.
  • Profund Advisors sold 31,759 Nurix Therapeutics shares in Q2 2026, an estimated $541K.
  • Nurix Therapeutics made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #388 holding.
  • Profund Advisors first reported a position in Nurix Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Profund Advisors's Nurix Therapeutics position peaked at $1.04M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.